| Prev Close | 262.00 |
| Day Low/High | 259.03 / 265.88 |
| 52 Wk Low/High | 142.61 / 275.87 |
Eli Lilly and Company (LLY)
260.37
NYSE
| Exchange | NYSE |
| Shares Outstanding | 956.59B |
| Market Cap | 250.63B |
| P/E Ratio | 33.79 |
| Div & Yield | N.A. (N.A) |
A Triangle Formation on Drug Maker Eli Lilly Is Ready for an Upside Breakout
The question is whether you want to buy before the breakout or after the breakout?
This Chart Pattern Hints at a Bullish Future
The bullish reversal pattern is appearing not just in single names, but also in whole sectors.
I Like What Eli Lilly Is Doing, but Have All the Horses Left the Barn?
Here are my thoughts on the quarter and trading the stock.
Employment Figures, Trading Thoughts, and 'Busting a Move'
Watching first-time jobless claims and trading volume, plus some thoughts on defense names like Raytheon and Lockheed Martin, and tech names like Lam Research.
Eli Lilly Surges to a New High and a New Price Target Opens Up
An inspiring performance.
You Can Gild the Lilly
Our technical strategy says that Eli Lilly can be bought on strength over $144, as the name looks more attractive along with others in the health care sector.
3 Strong Long-Term Buys for Uncertain Times
These pharmaceutical names have what it takes amid the current crisis and for the long run.
I Have More Hope for Eli Lilly's Research Partnership Than Its Charts
LLY is entering into a new partnership with AbCellera Biologics in an attempt to develop an antibody for Covid-19.
Jim Cramer: Do You Really Want to Sell Now?
The answer to that question depends on several factors, so let's break them down.
The Fed's Moves, Trading 5 Stocks, Coronavirus and the Market: Market Recon
It's no secret that the Fed would like to get out of the short-term repo business.
Adding to My Biotech Positions When Profit-Taking Hits
Here's my strategy which has worked particularly well.
All-Time Highs
It is nice to once again be sitting in for Doug Kass this Friday at the Daily Diary. I will be coming to you from a Starbucks in downtown Miami this morning, as the internet in my building has decided to opt for a three-day weekend. Oh, the perils o...
Biotech's Big Week Finds a Big Winner in Adaptimmune
The clinical stage company sees its shares climb after announcing some significant news during this week's J.P. Morgan Healthcare Conference.
4 Favorite Biotech Stock Picks for 2020
The Medical Technology Stock Letter's top pick rose 357% in 2019.
3 Powerhouse Pharma Stock Favorites
These healthcare stalwarts look attractive for growth and income.
Eli Lilly Has the Base to Support a New Rally
Shares of the pharmaceutical company received a quant upgrade Monday.
Jim Cramer: Nothing's Changed, Except the Prices
The market is throwing a Halloween sale right now that it doesn't need to throw, and that's an opportunity.
Jim Cramer: Drug Stocks Are Too Cheap
These stocks are priced for total imperfection. That's just what you want.
Jim Cramer: The Soundness of My Methods
A little bit of luck and a lot of homework can go a long way to make Big Money out of Mad Money. It's buying a Biogen, a Centene, or a Bristol-Myers that could do just that for you.
6 Top Biopharmaceutical Stock Picks You Should Know About
The aging population is creating a massive tailwind for companies that provide cutting-edge health care.
Jim Cramer: How to Survive This Violent Rotation
Emotions and panic must be checked at the door, if you are going to be a successful investor, especially right now.
A Sagging Drugmaker and Lagging Pet Health Name Both Worth Looks
Alexion Pharmaceuticals and Elanco Animal Health have seen their shares go to the dogs of late, but still offer reasons for portfolio consideration.
Trading Apple and Netflix, Beyond Meat Earnings: Market Recon
Overall, expect trading volume, with notable exception of action in specific names reporting earnings, to remain on the light side right through later Wednesday afternoon.
Here's a Prescription for Eli Lilly Stock: Don't Swallow Yet
With prices in a downtrend with a $95 price target, hold off on purchases until prices hold for the drugmaker.
My 3 Predictions for the Second Half of 2019
Watch the Russell 2000, housing activity, and mergers and acquisitions.
AbbVie Joins Giant Acquisition Trend in Big Pharma With Allergan Deal
The proposed, $63 billion transaction is the latest deal in an industry where it can be cheaper to buy the science of another company than develop products.
